Splenic radiation for corticosteroid-resistant immune thrombocytopenia

David Calverley, Glenn W. Jones, John G. Kelton

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Objective: To determine the role of splenic radiation as a treatment for immune thrombocytopenia. Design: Retrospective analysis of an open, nonrandomized investigation. Setting: A regional cancer center, referred care, and primary care settings. Patients: Eleven older patients with idiopathic thrombocytopenic purpura (ITP) and 8 patients with secondary immune thrombocytopenia refractory to corticosteroid treatment for whom surgery would have posed a high risk. Intervention: A short course (1 to 6 weeks) of radiation therapy to the spleen (total dose, 75 to 1370 cGy) with or without concurrent and postradiation corticosteroid administration. Measurements: Efficacy was assessed by measuring any increase in the platelet count and by monitoring the duration of response and side effects. Results: Of 11 patients with ITP, 8 patients responded. Three patients had a sustained (> 52 weeks) increase in the platelet count to safe levels after therapy was discontinued. An additional patient had a sustained response but required intermittent, low-dose corticosteroids. Four other patients had increases in their platelet counts that lasted from 8 to 25 weeks. Two of the eight patients without ITP had a positive response, whereas four did not respond, and two were not evaluable. Patients had no adverse reactions to the radiation treatment. Conclusion: Splenic radiation can be a safe and effective method to raise the platelet count in older patients with ITP that is refractory to corticosteroids and in whom the risks associated with splenectomy are high.

Original languageEnglish (US)
Pages (from-to)977-981
Number of pages5
JournalAnnals of Internal Medicine
Volume116
Issue number12
StatePublished - Jun 15 1992
Externally publishedYes

Fingerprint

Idiopathic Thrombocytopenic Purpura
Adrenal Cortex Hormones
Radiation
Platelet Count
Splenectomy
Therapeutics
Primary Health Care
Radiotherapy
Spleen

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Calverley, D., Jones, G. W., & Kelton, J. G. (1992). Splenic radiation for corticosteroid-resistant immune thrombocytopenia. Annals of Internal Medicine, 116(12), 977-981.

Splenic radiation for corticosteroid-resistant immune thrombocytopenia. / Calverley, David; Jones, Glenn W.; Kelton, John G.

In: Annals of Internal Medicine, Vol. 116, No. 12, 15.06.1992, p. 977-981.

Research output: Contribution to journalArticle

Calverley, D, Jones, GW & Kelton, JG 1992, 'Splenic radiation for corticosteroid-resistant immune thrombocytopenia', Annals of Internal Medicine, vol. 116, no. 12, pp. 977-981.
Calverley D, Jones GW, Kelton JG. Splenic radiation for corticosteroid-resistant immune thrombocytopenia. Annals of Internal Medicine. 1992 Jun 15;116(12):977-981.
Calverley, David ; Jones, Glenn W. ; Kelton, John G. / Splenic radiation for corticosteroid-resistant immune thrombocytopenia. In: Annals of Internal Medicine. 1992 ; Vol. 116, No. 12. pp. 977-981.
@article{065620e14b5941fb8e727bff270edf5f,
title = "Splenic radiation for corticosteroid-resistant immune thrombocytopenia",
abstract = "Objective: To determine the role of splenic radiation as a treatment for immune thrombocytopenia. Design: Retrospective analysis of an open, nonrandomized investigation. Setting: A regional cancer center, referred care, and primary care settings. Patients: Eleven older patients with idiopathic thrombocytopenic purpura (ITP) and 8 patients with secondary immune thrombocytopenia refractory to corticosteroid treatment for whom surgery would have posed a high risk. Intervention: A short course (1 to 6 weeks) of radiation therapy to the spleen (total dose, 75 to 1370 cGy) with or without concurrent and postradiation corticosteroid administration. Measurements: Efficacy was assessed by measuring any increase in the platelet count and by monitoring the duration of response and side effects. Results: Of 11 patients with ITP, 8 patients responded. Three patients had a sustained (> 52 weeks) increase in the platelet count to safe levels after therapy was discontinued. An additional patient had a sustained response but required intermittent, low-dose corticosteroids. Four other patients had increases in their platelet counts that lasted from 8 to 25 weeks. Two of the eight patients without ITP had a positive response, whereas four did not respond, and two were not evaluable. Patients had no adverse reactions to the radiation treatment. Conclusion: Splenic radiation can be a safe and effective method to raise the platelet count in older patients with ITP that is refractory to corticosteroids and in whom the risks associated with splenectomy are high.",
author = "David Calverley and Jones, {Glenn W.} and Kelton, {John G.}",
year = "1992",
month = "6",
day = "15",
language = "English (US)",
volume = "116",
pages = "977--981",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "12",

}

TY - JOUR

T1 - Splenic radiation for corticosteroid-resistant immune thrombocytopenia

AU - Calverley, David

AU - Jones, Glenn W.

AU - Kelton, John G.

PY - 1992/6/15

Y1 - 1992/6/15

N2 - Objective: To determine the role of splenic radiation as a treatment for immune thrombocytopenia. Design: Retrospective analysis of an open, nonrandomized investigation. Setting: A regional cancer center, referred care, and primary care settings. Patients: Eleven older patients with idiopathic thrombocytopenic purpura (ITP) and 8 patients with secondary immune thrombocytopenia refractory to corticosteroid treatment for whom surgery would have posed a high risk. Intervention: A short course (1 to 6 weeks) of radiation therapy to the spleen (total dose, 75 to 1370 cGy) with or without concurrent and postradiation corticosteroid administration. Measurements: Efficacy was assessed by measuring any increase in the platelet count and by monitoring the duration of response and side effects. Results: Of 11 patients with ITP, 8 patients responded. Three patients had a sustained (> 52 weeks) increase in the platelet count to safe levels after therapy was discontinued. An additional patient had a sustained response but required intermittent, low-dose corticosteroids. Four other patients had increases in their platelet counts that lasted from 8 to 25 weeks. Two of the eight patients without ITP had a positive response, whereas four did not respond, and two were not evaluable. Patients had no adverse reactions to the radiation treatment. Conclusion: Splenic radiation can be a safe and effective method to raise the platelet count in older patients with ITP that is refractory to corticosteroids and in whom the risks associated with splenectomy are high.

AB - Objective: To determine the role of splenic radiation as a treatment for immune thrombocytopenia. Design: Retrospective analysis of an open, nonrandomized investigation. Setting: A regional cancer center, referred care, and primary care settings. Patients: Eleven older patients with idiopathic thrombocytopenic purpura (ITP) and 8 patients with secondary immune thrombocytopenia refractory to corticosteroid treatment for whom surgery would have posed a high risk. Intervention: A short course (1 to 6 weeks) of radiation therapy to the spleen (total dose, 75 to 1370 cGy) with or without concurrent and postradiation corticosteroid administration. Measurements: Efficacy was assessed by measuring any increase in the platelet count and by monitoring the duration of response and side effects. Results: Of 11 patients with ITP, 8 patients responded. Three patients had a sustained (> 52 weeks) increase in the platelet count to safe levels after therapy was discontinued. An additional patient had a sustained response but required intermittent, low-dose corticosteroids. Four other patients had increases in their platelet counts that lasted from 8 to 25 weeks. Two of the eight patients without ITP had a positive response, whereas four did not respond, and two were not evaluable. Patients had no adverse reactions to the radiation treatment. Conclusion: Splenic radiation can be a safe and effective method to raise the platelet count in older patients with ITP that is refractory to corticosteroids and in whom the risks associated with splenectomy are high.

UR - http://www.scopus.com/inward/record.url?scp=0026696047&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026696047&partnerID=8YFLogxK

M3 - Article

C2 - 1586107

AN - SCOPUS:0026696047

VL - 116

SP - 977

EP - 981

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 12

ER -